Literature DB >> 22993636

Clinical application of positron emission tomography in designing radiation fields in non-small cell lung cancer patients.

Alexander Lin1, Charles Wood, Christine Hill-Kayser, Rosemarie Mick, Larry Kaiser, James Metz.   

Abstract

There is significant interest in incorporating positron emission tomography (PET) into radiation therapy planning, although limited data exist that separately consider its diagnostic accuracy with respect to the primary tumor, hilum and mediastinum. This study evaluates the accuracy of PET planning by region of interest. Between January 2003 and July 2005, 351 patients with a pre-operative PET study underwent surgical resection. Of this population, 257 (73%) patients with a diagnosis of non-small cell lung cancer were evaluated. PET study findings regarding the suspected primary tumor site, ipsilateral hilum and mediastinum were correlated with surgical pathology for determination of accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). The accuracy of the primary site (95%), ipsilateral hilum (80%) and mediastinum (84%) was relatively high. The NPV of the ipsilateral hilum and mediastinum was also high (92 and 86%, respectively). However, the PPV of the ipsilateral hilum (31%) and mediastinum (75%) was lower. PET accuracy evaluating bronchoalveolar primary tumors was lower vs. other histologies (86 vs. 96%, p=0.02), although there was no difference with regard to the hilum or mediastinum. PET scanning may be an important tool in designing radiation treatment fields for lung cancer when combined with other imaging modalities. However, caution must be exercised when evaluating lymph node regions, as the PPV is not as high for the ipsilateral hilum and mediastinum as for the primary tumor. The NPV is high for nodal regions and may help with the exclusion of large treatment volumes in selected cases.

Entities:  

Year:  2010        PMID: 22993636      PMCID: PMC3446737          DOI: 10.3892/etm.2010.153

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  33 in total

1.  Comparison of imaging TNM [(i)TNM] and pathological TNM [pTNM] in staging of bronchogenic carcinoma.

Authors:  A Gdeedo; P Van Schil; B Corthouts; F Van Mieghem; J Van Meerbeeck; E Van Marck
Journal:  Eur J Cardiothorac Surg       Date:  1997-08       Impact factor: 4.191

2.  Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography.

Authors:  R C Hagberg; G M Segall; P Stark; T A Burdon; M F Pompili
Journal:  Eur J Cardiothorac Surg       Date:  1997-07       Impact factor: 4.191

3.  The impact of positron emission tomography on clinical decision making in a university-based multidisciplinary lung cancer practice.

Authors:  Sharona Sachs; Thomas V Bilfinger
Journal:  Chest       Date:  2005-08       Impact factor: 9.410

4.  Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.

Authors:  J F Vansteenkiste; S G Stroobants; P R De Leyn; P J Dupont; J Bogaert; A Maes; G J Deneffe; K L Nackaerts; J A Verschakelen; T E Lerut; L A Mortelmans; M G Demedts
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

5.  Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer.

Authors:  Rosalie C Viney; Michael J Boyer; Madeleine T King; Patricia M Kenny; Christine A Pollicino; Jocelyn M McLean; Brian C McCaughan; Michael J Fulham
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

6.  The accuracy of clinical evaluative intrathoracic staging in lung cancer as assessed by postsurgical pathologic staging.

Authors:  H C Fernando; P Goldstraw
Journal:  Cancer       Date:  1990-06-01       Impact factor: 6.860

7.  Preoperative staging of lung cancer with combined PET-CT.

Authors:  Barbara Fischer; Ulrik Lassen; Jann Mortensen; Søren Larsen; Annika Loft; Anne Bertelsen; Jesper Ravn; Paul Clementsen; Asbjørn Høgholm; Klaus Larsen; Torben Rasmussen; Susanne Keiding; Asger Dirksen; Oke Gerke; Birgit Skov; Ida Steffensen; Hanne Hansen; Peter Vilmann; Grete Jacobsen; Vibeke Backer; Niels Maltbaek; Jesper Pedersen; Henrik Madsen; Henrik Nielsen; Liselotte Højgaard
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

8.  A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.

Authors:  Shuanghu Yuan; Xindong Sun; Minghuan Li; Jinming Yu; Ruimei Ren; Yonghu Yu; Jianbin Li; Xiuqing Liu; Renben Wang; Baosheng Li; Li Kong; Yong Yin
Journal:  Am J Clin Oncol       Date:  2007-06       Impact factor: 2.339

9.  New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification.

Authors:  H Bülzebruck; R Bopp; P Drings; E Bauer; S Krysa; G Probst; G van Kaick; K M Müller; I Vogt-Moykopf
Journal:  Cancer       Date:  1992-09-01       Impact factor: 6.860

Review 10.  Noninvasive staging of non-small cell lung cancer: a review of the current evidence.

Authors:  Eric M Toloza; Linda Harpole; Douglas C McCrory
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.